NeoGenomics, Inc. (NASDAQ:NEO) General Counsel Alicia C. Olivo Sells 5,175 Shares

NeoGenomics, Inc. (NASDAQ:NEO) General Counsel Alicia C. Olivo sold 5,175 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $15.36, for a total value of $79,488.00. Following the completion of the sale, the general counsel now owns 37,129 shares in the company, valued at approximately $570,301.44. The trade was a 12.23 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

NeoGenomics Price Performance

Shares of NASDAQ NEO opened at $15.36 on Thursday. The business has a 50-day moving average price of $14.66 and a 200 day moving average price of $14.82. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.99 and a quick ratio of 1.91. NeoGenomics, Inc. has a 52-week low of $12.77 and a 52-week high of $21.22.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.01 by $0.04. The firm had revenue of $167.80 million during the quarter, compared to the consensus estimate of $167.00 million. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The firm’s revenue was up 10.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.06) EPS. Equities analysts predict that NeoGenomics, Inc. will post -0.17 EPS for the current year.

Hedge Funds Weigh In On NeoGenomics

Large investors have recently modified their holdings of the business. Arizona State Retirement System increased its stake in NeoGenomics by 2.0% in the 2nd quarter. Arizona State Retirement System now owns 35,739 shares of the medical research company’s stock valued at $496,000 after purchasing an additional 708 shares in the last quarter. Crossmark Global Holdings Inc. grew its holdings in NeoGenomics by 2.9% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 29,494 shares of the medical research company’s stock valued at $409,000 after buying an additional 842 shares during the last quarter. Fernwood Investment Management LLC boosted its holdings in shares of NeoGenomics by 1.0% during the third quarter. Fernwood Investment Management LLC now owns 89,500 shares of the medical research company’s stock worth $1,320,000 after purchasing an additional 900 shares during the last quarter. FMR LLC boosted its holdings in shares of NeoGenomics by 7.6% during the third quarter. FMR LLC now owns 13,255 shares of the medical research company’s stock worth $196,000 after purchasing an additional 931 shares during the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of NeoGenomics by 42.3% during the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after purchasing an additional 987 shares during the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on NEO shares. Benchmark reaffirmed a “buy” rating and set a $18.00 price objective on shares of NeoGenomics in a research report on Tuesday, September 24th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of NeoGenomics in a research report on Wednesday, November 6th. Finally, Stephens reiterated an “overweight” rating and set a $19.00 price target on shares of NeoGenomics in a research report on Tuesday, July 30th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, NeoGenomics presently has an average rating of “Buy” and an average target price of $20.25.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.